hope
charity
love
hope
charity
love
hope
charity
love

Ella's Story

We have established the Hope Foundation to care for Aussie families and kids in desperate situations. They may need medical care or life-saving drugs that they simply cannot afford. Our purpose is to provide financial assistance to these people. There are many stories and this is just one. The story of Ella Sparkes and family...

Ella was born with a very rare syndrome called Fetal Valproate Syndrome, which requires numerous surgeries, regular check-ups and tests at The Royal Children's Hospital in Melbourne. This may be necessary for the rest of her life.

Ella and her family need to travel regularly between home (Albury NSW) and The Royal Children's Hospital Melbourne.
This takes a toll on family finances, as accommodation and travel costs are required for each trip. Each stay can last anywhere from two days to a week, maybe longer depending on the procedures required to be done at the time.

Please support Ella Sparkes, her sister who also need a little help and the Sparkes' Family, to meet all their medical expenses.
​​The Hope Foundation guarantees that 100% of all contributions will reach this family.  Thank You!

ViEW A FEW
PICTURES

Click here
Syndrome Details
Symptoms
Causes
Affected Populations

  Fetal Valproate Syndrome is a rare congenital disorder caused by exposure of the fetus to valproic acid (dalpro, depakene, depakote, depakote sprinkle, divalproex, epival, myproic acid) during the first three months of pregnancy. Valproic acid is an anticonvulsant drug used to control certain types of seizures in the treatment of epilepsy. A small percentage of pregnant women who take this medication can have a child with Fetal Valproate Syndrome. The exact prevalence of this condition remains to be established. Symptoms of this disorder may include spina bifida, distinctive facial features, and other musculoskeletal abnormalities.

Infants with Fetal Valproate Syndrome may be born with spina bifida. Spina bifida is the incomplete closure of bony spine. It occurs when the tube of tissue that lies along the center of the early embryo (neural tube) does not completely fuse during fetal growth. Part of the contents of the spinal canal may protrude through this opening (bifida cystica). Depending on the severity of the opening, a variety of neurological and physical symptoms may occur. (For more information on this disorder choose "Spina Bifida as your search term in the Rare Disease Database.)

Distinctive facial features are characteristic of Fetal Valproate Syndrome. Affected infants may have a vertical fold of skin on either side of the nose that forms a groove under the eye (epicanthal folds); a small, upturned nose with a flat bridge; a small mouth (microstomia); a long, thin, upper lip; a downturned mouth; and/or minor abnormalities of the ears.

Other abnormalities that may be found in a few affected individuals include: underdeveloped nails of the fingers and toes; dislocation of the hip; long, thin fingers and toes (arachnodactyly); overlapping fingers and toes; separation of the rectus muscle of the abdominal wall (diastasis recti); absence of the first rib; a condition in which the urinary opening is on the underside of the penis (hypospadias); abnormalities of the heart; softening of the windpipe (tracheomalacia); and/or a club foot.

Growth deficiency and an unusually small head (microcephaly) may also occur when valproic acid is taken in combination with other anticonvulsant drugs during pregnancy.

Fetal Valproate Syndrome is a rare disorder that may occur when a fetus is exposed to valproic acid (depakene, dalpro, myproic acid, depakote, depakote sprinkle, divalproex, epival) during the first three months of pregnancy. It is believed that valproic acid crosses the placenta and interferes with normal development causing developmental abnormalities in the fetus (teratogenesis). Some researchers feel that the severity of the defects caused by valproic acid may be dosage related while others have found no dose-related effect.

Valproic acid in combination with other anticonvulsant drugs may also cause fetal abnormalities.

Fetal Valproate Syndrome affects males and females in equal numbers. Spina Bifida is found in approximately 1-5% of those exposed to valproic acid during fetal development. Facial abnormalities have been found in almost half of the children exposed to valproic acid in utero. There were approximately 175 cases of Fetal Valproate Syndrome reported internationally between 1974 and 1988.

Like us on

facebook

Follow us on

twitter

Click here

HOPE foundation

Post Office
​​Tangambalanga

VIC. 3691

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Phone: 0437 680 707

hopecharity@safe-mail.net

Click here